Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 9, 2017 - Issue
Submit an article Journal homepage
80
Views
17
CrossRef citations to date
0
Altmetric
Original Research

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

Dolores Isla1 Medical Oncology Department, Clinical Universitary Hospital Lozano Blesa, Zaragoza
,
Javier De Castro2 Medical Oncology Department, Universitary Hospital La Paz, Madrid
,
Oscar Juan3 Medical Oncology Department, Universitary and Polytechnic Hospital La Fe, Valencia
,
Santiago Grau4 Pharmacy Department, Del Mar Hospital, Barcelona
,
Javier Orofino5 Roche Farma, S.A., Health Economics
,
Rocío Gordo5 Roche Farma, S.A., Health Economics
,
Carlos Rubio-Terrés6 Health Value, Health Economics, Madrid, Spain
&
Darío Rubio-Rodríguez6 Health Value, Health Economics, Madrid, SpainCorrespondence[email protected]
 show all
Pages 31-38 | Published online: 30 Dec 2016

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.